Literature DB >> 19556259

Recurrent vasovagal syncope: comparison between clomipramine and nitroglycerin as drug challenges during head-up tilt testing.

Panayota Flevari1, Dionyssios Leftheriotis, Christophoros Komborozos, Katerina Fountoulaki, Nikolaos Dagres, George Theodorakis, Dimitrios Kremastinos.   

Abstract

AIMS: To compare the responses between clomipramine, a centrally acting substance, and nitroglycerin, with mainly peripheral action, when each drug is used during tilt test for the induction of vasovagal syncope (VVS). METHODS AND
RESULTS: Hundred patients with recurrent episodes of classical VVS underwent two tilt tests in a randomized sequence. One test included 20 min of tilt at 60 degrees with intravenous administration of 5 mg clomipramine (clomipramine tilt), whereas the other test included an initial 30 min period of passive 60 degrees tilt, followed by sublingual spray administration of 400 microg nitroglycerin (nitroglycerin tilt). Fifty asymptomatic subjects served as controls. Following clomipramine tilt, a positive response occurred in 73 patients (73%), a negative response in 23 (23%), and drug intolerance in 4 (4%). With nitroglycerin tilt, these percentages were 52, 48, and 0%, respectively. Significant differences were observed regarding positive responses (clomipramine vs. nitroglycerin: 73/100 vs. 52/100, P < 0.05), as well as negative responses (23/100 vs. 48/100, respectively, P < 0.05). A high concordance rate was observed in positive responses.
CONCLUSION: In the evaluation of patients with recurrent classical VVS, clomipramine tilt is associated with an increased positive yield relative to nitroglycerin tilt. This suggests that central mechanisms may be more important than peripheral ones in VVS pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19556259     DOI: 10.1093/eurheartj/ehp255

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  9 in total

1.  The pathophysiologic mechanisms associated with hypotensive susceptibility.

Authors:  Ashish Chaddha; Martina Rafanelli; Michele Brignole; Richard Sutton; Kevin E Wenzke; Stephen L Wasmund; Richard L Page; Mohamed H Hamdan
Journal:  Clin Auton Res       Date:  2016-06-20       Impact factor: 4.435

Review 2.  Head Up Tilt Testing: An Appraisal of Its Current Role in the Management of Patients with Syncope.

Authors:  Paula Macedo; Luiz Roberto Leite; Samuel J Asirvatham; Denise Tessariol Hachul; Leopoldo Luiz Dos Santos-Neto; Win-Kuang Shen
Journal:  J Atr Fibrillation       Date:  2011-07-15

3.  Management and therapy of vasovagal syncope: A review.

Authors:  Muhammet Ali Aydin; Tushar V Salukhe; Iris Wilke; Stephan Willems
Journal:  World J Cardiol       Date:  2010-10-26

Review 4.  Current approach to the treatment of vasovagal syncope in adults.

Authors:  Tarek Hatoum; Satish Raj; Robert Stanley Sheldon
Journal:  Intern Emerg Med       Date:  2022-09-18       Impact factor: 5.472

Review 5.  [Management of syncope in clinical practice : What has changed according to the new ESC guidelines 2018?]

Authors:  S Oebel; G Hindricks
Journal:  Herz       Date:  2018-12       Impact factor: 1.443

6.  Randomized Prospective Comparison of Two Protocols for Head-up Tilt Testing in Patients with Normal Heart and Recurrent Unexplained Syncope.

Authors:  Mohammad Alasti; Mohammad Hosein Nikoo; Mohommad Hosein Jadbabaei; Masoud Seyedian; Babak Payami; Saman Taghavianpour; Bita Omidvar; Maryam Maghoumizadeh; Nasim Azadi
Journal:  Indian Pacing Electrophysiol J       Date:  2013-11-15

Review 7.  Role of head-up tilt table testing in patients with syncope or transient loss of consciousness.

Authors:  Toshiyuki Furukawa
Journal:  J Arrhythm       Date:  2017-09-06

8.  Recurrent seizures in a young woman: when video-EEG diagnoses a cardiac cause: a case report.

Authors:  Corentin Chaumont; Julie Bourilhon; Nathalie Chastan; Adrian Mirolo; Hélène Eltchaninoff; Frédéric Anselme
Journal:  Eur Heart J Case Rep       Date:  2020-09-19

9.  Tilt testing remains a valuable asset.

Authors:  Richard Sutton; Artur Fedorowski; Brian Olshansky; J Gert van Dijk; Haruhiko Abe; Michele Brignole; Frederik de Lange; Rose Anne Kenny; Phang Boon Lim; Angel Moya; Stuart D Rosen; Vincenzo Russo; Julian M Stewart; Roland D Thijs; David G Benditt
Journal:  Eur Heart J       Date:  2021-05-01       Impact factor: 35.855

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.